G. Pugnet

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Pierre Charles, Benjamin Terrier, Élodie Perrodeau et al. · Annals of the Rheumatic Diseases · 2018 · 336 citations

Life Sciences, Immunology, Pharmacotherapy +15

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 291 citations · Full text

Life Sciences, Immunology, Internal Medicine +14

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Pierre Charles, Élodie Perrodeau, M. Samson et al. · Annals of Internal Medicine · 2020 · 193 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)

Boris Bienvenu, K.H. Ly, M. Lambert et al. · La Revue de Médecine Interne · 2016 · 191 citations

Medicine, Clinical Sciences, Internal Medicine +10

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

Hélène Vallet, P. Sève, Lucie Biard et al. · Arthritis & Rheumatology · 2016 · 175 citations

Pharmacy, Immunology, Pharmacotherapy +16